Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon Alfa-2b with Polyvalent Melanoma Vaccine in Stage III Melanoma
NCT00004104Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Jun 1998
- Primary completion
- Jul 2000
- Modality
- Whole Cell Cancer Vaccines, Cytokines & Interferons, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised trial of polyvalent melanoma vaccine and interferon alfa-2b in cutaneous melanoma (CM) (3 arms), sponsored by NYU Langone Health. Primary endpoint: Potentiation of antimelanoma antibodies and cellular immune responses. Started Jun 1998; status: completed.
02
Drugs
polyvalent melanoma vaccineinterferon alfa-2b
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT00004104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004104.